Mizuho initiated coverage of Select Medical (SEM) with an Outperform rating and $25 price target The firm believes Select is an attractive long-term investment opportunity given the company’s leading position in the post-acute continuum of care, attractive growth profile, improved leverage profile and attractive valuation. Earnings visibility is solid for Select Medical given the company’s “continued diversification and acceleration into fast-growing” inpatient rehabilitation, coupled with margin expansion potential in outpatient rehabilitation, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SEM:
- Select Medical price target lowered to $23 from $47 at RBC Capital
- Benchmark upgrades Select Medical, sees attractive entry point after pullback
- Select Medical upgraded to Buy from Hold at Benchmark
- Select Medical Faces Financial Risks Amid Separation Agreement with Concentra
- Select Medical Reports Growth and Strategic Moves
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue